title: Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders.
authors.forename: Femke H
authors.initials: FH
authors.lastname: Bouwman
authors.forename: Wiesje M
authors.initials: WM
authors.lastname: van der Flier
authors.forename: Niki S M
authors.initials: NS
authors.lastname: Schoonenboom
authors.forename: Evert J
authors.initials: EJ
authors.lastname: van Elk
authors.forename: Astrid
authors.initials: A
authors.lastname: Kok
authors.forename: Philip
authors.initials: P
authors.lastname: Scheltens
authors.forename: Marinus A
authors.initials: MA
authors.lastname: Blankenstein
mesh_terms: D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008137:Longitudinal Studies; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D013048:Specimen Handling; D013997:Time Factors
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)